Evidence map›Paper›PMID 34268417›Full record

ArticleAnnals of translational medicine2021

Evaluation of dynamic image progression of minimally invasive and preinvasive lung adenocarcinomas.

Tianxiang Chen, Xiaocheng Zhang, Alessio Campisi, Angelo Paolo Ciarrocchi, Andrea Dell'Amore, Liwei Song, Yunhai Yang, Chengshui Chen, Qingquan Luo

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Tianxiang ChenShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xiaocheng ZhangDepartment of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Alessio CampisiShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Angelo Paolo CiarrocchiThoracic Surgery Unit, Department of Thoracic Diseases, University of Bologna, G.B. Morgagni-L. Pierantoni Hospital, Forlì, Italy.
Andrea Dell'AmoreDivision of Thoracic Surgery, Department of Cardiothoracic Surgery and Vascular Sciences, Padua University Hospital, University of Padua, Padua, Italy.
Liwei SongShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Yunhai YangShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Chengshui ChenDepartment of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Qingquan LuoShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Jiao Tong University · CNOspedale G.B. Morgagni - L.Pierantoni · ITWenzhou Medical University · CNShanghai Chest Hospital · CNUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe target of our study was to investigate if the size (greater than and less than 1 cm) of ground-glass opacities (GGOs) of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) of the lung influences the rate of their evolution.

methodsWe retrospectively analyzed patients with AIS and MIA who underwent surgery at Shanghai Chest Hospital, Shanghai Jiao Tong University between January 2018 and July 2019, focusing on histopathology, surgical procedure, epidermal growth factor receptor (EGFR) mutations, and computed tomography (CT) images.

resultsA total of 224 AIS (n=117) and MIA (n=107) tumors were analyzed. The patients with a tumor diameter <1 cm were distinctly younger than those with tumors >1 cm in size (P<0.001). Pure ground-glass opacities (pGGO) occurred significantly more in patients with nodules <1 cm, while part-solid/mixed ground-glass opacities (mGGO) predominated in patients with nodules >1 cm (P=0.047). There was no significant difference in GGO evolution for GGOs of different sizes. Mutations of EGFR were more common in patients with MIA than in those with AIS (P<0.001).

conclusionsWe found that GGO size and variation (pGGO or mGGO) did not correlate to tumor stability, therefore larger GGOs can undergo standard follow-up protocols to evaluate their evolution over time.

Indexed as

adenocarcinoma in situ (AIS)follow-upGround-glass opacities (GGOs)minimally invasive adenocarcinoma (MIA)progressionsize

Identifiers

PMID34268417
PMCPMC8246155
OpenAlexW3162860286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.